Ross Wilson is a principal investigator at the University of California, Berkeley, leading a team at the Innovative Genomics Institute. Dr. Wilson is working to enable widespread clinical use of genome-editing enzymes, which is currently limited by the challenge of delivering enzyme therapeutics to the cells in need of correction. To address this need, the Wilson lab relies on protein/RNA engineering to create safe, effective methods of administration, as well as targeting delivery to specific cells, tissues, or organs. These tools will help genome editing make the leap from the lab to the clinic.